Introduction: Uremic patients exhibit remarkably increased rates of mortality and cardiovascular (CV) events, but risk prediction in this setting remains difficult. Systemic mitochondrial dysfunction is pervasive in end-stage kidney disease and may contribute to CV complications. We tested the clinical significance of circulating MOTS-c, a small mitochondrial-derived peptide, as a biomarker for improving mortality and CV risk prediction in hemodialysis (HD) patients. Methods: We conducted a prospective, observational, multicenter study on 94 prevalent HD patients. The study endpoint was a composite of all-cause mortality and non-fatal CV events. The diagnostic and prognostic capacities of predictive models based on cohort-related risk factors were tested before and after the inclusion of MOTS-c. Results: MOTS-c levels were higher in HD patients than in controls (p < 0.001) and even more elevated (p = 0.01) in the 53 individuals experiencing the combined endpoint during follow-up (median duration: 26.5 months). MOTS-c was independently associated with the endpoint at either multivariate logistic (OR 1.020; 95% CI: 1.011–1.109; p = 0.03) or Cox regression analyses (HR 1.004; 95% CI: 1.000–1.025; p = 0.05) and the addition of this biomarker to prognostic models including the other cohort-related risk predictors (age, left ventricular mass, evidence of diastolic dysfunction, diabetes, pulse pressure) significantly improved the calibration, risk variability explanation, discrimination (receiver operating characteristic area under the curve from 0.727 to 0.743; C-index from 0.658 to 0.700), and particularly, the overall reclassification capacity (NRI 15.87%; p = 0.01). Conclusions: In HD patients, the mitochondrial-derived peptide MOTS-c may impart significant information to refine CV risk prediction, beyond cohort-related risk factors. Future investigations are needed to generalize these findings in larger and more heterogeneous cohorts.

1.
Kovesdy
CP
.
Epidemiology of chronic kidney disease: an update 2022
.
Kidney Int Suppl
.
2022
;
12
(
1
):
7
11
.
2.
Jankowski
J
,
Floege
J
,
Fliser
D
,
Bohm
M
,
Marx
N
.
Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options
.
Circulation
.
2021
;
143
(
11
):
1157
72
.
3.
Foreman
KJ
,
Marquez
N
,
Dolgert
A
,
Fukutaki
K
,
Fullman
N
,
McGaughey
M
, et al
.
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories
.
Lancet
.
2018
;
392
(
10159
):
2052
90
.
4.
Li
X
,
Lindholm
B
.
Cardiovascular risk prediction in chronic kidney disease
.
Am J Nephrol
.
2022
;
53
(
10
):
730
9
.
5.
Gan
T
,
Guan
H
,
Li
P
,
Huang
X
,
Li
Y
,
Zhang
R
, et al
.
Risk prediction models for cardiovascular events in hemodialysis patients: a systematic review
.
Semin Dial
;
2023
.
6.
Wan
W
,
Zhang
L
,
Lin
Y
,
Rao
X
,
Wang
X
,
Hua
F
, et al
.
Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
.
J Transl Med
.
2023
;
21
(
1
):
36
.
7.
Tang
M
,
Su
Q
,
Duan
Y
,
Fu
Y
,
Liang
M
,
Pan
Y
, et al
.
The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury
.
Sci Rep
.
2023
;
13
(
1
):
19781
.
8.
Kadlec
AO
,
Beyer
AM
,
Ait-Aissa
K
,
Gutterman
DD
.
Mitochondrial signaling in the vascular endothelium: beyond reactive oxygen species
.
Basic Res Cardiol
.
2016
;
111
(
3
):
26
.
9.
Mohtashami
Z
,
Singh
MK
,
Salimiaghdam
N
,
Ozgul
M
,
Kenney
MC
.
MOTS-C, the most recent mitochondrial derived peptide in human aging and age-related diseases
.
Int J Mol Sci
.
2022
;
23
(
19
):
11991
.
10.
Reynolds
JC
,
Lai
RW
,
Woodhead
JST
,
Joly
JH
,
Mitchell
CJ
,
Cameron-Smith
D
, et al
.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
.
Nat Commun
.
2021
;
12
(
1
):
470
.
11.
Ramanjaneya
M
,
Bettahi
I
,
Jerobin
J
,
Chandra
P
,
Abi Khalil
C
,
Skarulis
M
, et al
.
Mitochondrial-derived peptides are down regulated in diabetes subjects
.
Front Endocrinol
.
2019
;
10
:
331
.
12.
Luo
YH
,
Xie
L
,
Li
JY
,
Xie
Y
,
Li
MQ
,
Zhou
L
.
Serum MOTS-C levels are decreased in obese children and associated with vascular endothelial function
.
Diabetes Metab Syndr Obes
.
2023
;
16
:
1013
20
.
13.
Qin
Q
,
Delrio
S
,
Wan
J
,
Jay Widmer
R
,
Cohen
P
,
Lerman
LO
, et al
.
Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction
.
Int J Cardiol
.
2018
;
254
:
23
7
.
14.
Cakmak
T
,
Yasar
E
,
Cakmak
E
,
Tekin
S
,
Karakus
Y
,
Turkoglu
C
, et al
.
Evaluation of coronary flow level with mots-C in patients with STEMI undergoing primary PCI
.
Arq Bras Cardiol
.
2023
;
120
(
1
):
e20220358
.
15.
Liu
C
,
Gidlund
EK
,
Witasp
A
,
Qureshi
AR
,
Söderberg
M
,
Thorell
A
, et al
.
Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease
.
Am J Physiol Ren Physiol
.
2019
;
317
(
5
):
F1122
f1131
.
16.
Lang
RM
,
Badano
LP
,
Mor-Avi
V
,
Afilalo
J
,
Armstrong
A
,
Ernande
L
, et al
.
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
J Am Soc Echocardiogr
.
2015
;
16
(
3
):
233
70
.
17.
Tripepi
G
,
Jager
KJ
,
Dekker
FW
,
Zoccali
C
.
Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination
.
Nephrol Dial Transpl
.
2010
;
25
(
5
):
1399
401
.
18.
Tripepi
G
,
Jager
KJ
,
Dekker
FW
,
Zoccali
C
.
Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification
.
Nephrol Dial Transpl
.
2010
;
25
(
5
):
1402
5
.
19.
Zheng
Y
,
Wei
Z
,
Wang
T
.
MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation
.
Front Endocrinol
.
2023
;
14
:
1120533
.
20.
Srivastava
A
,
Tomar
B
,
Sharma
D
,
Rath
SK
.
Mitochondrial dysfunction and oxidative stress: role in chronic kidney disease
.
Life Sci
.
2023
;
319
:
121432
.
21.
Libetta
C
,
Sepe
V
,
Esposito
P
,
Galli
F
,
Dal Canton
A
.
Oxidative stress and inflammation: implications in uremia and hemodialysis
.
Clin Biochem
.
2011
;
44
(
14–15
):
1189
98
.
22.
Wathanavasin
W
,
Banjongjit
A
,
Avihingsanon
Y
,
Praditpornsilpa
K
,
Tungsanga
K
,
Eiam-Ong
S
, et al
.
Prevalence of sarcopenia and its impact on cardiovascular events and mortality among dialysis patients: a systematic review and meta-analysis
.
Nutrients
.
2022
;
14
(
19
):
4077
.
You do not currently have access to this content.